{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:24:36Z","timestamp":1791329076424,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study is to address the safety and effectiveness of a second continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) treatment by comparing its outcome against a first CW-TSCPC treatment in the same patients with refractory glaucoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-one eyes with either primary or secondary glaucoma received a second CW-TSCPC laser session\u2009\u2265\u20093\u00a0months after the first treatment. Intraocular pressure (IOP), best-corrected visual acuity (BCVA), and number of topical or oral ophthalmic pressure-reducing medications were registered at every time point up to the last follow-up at 3\u00a0months. A complete slit-lamp examination was conducted to record for complications or other abnormal ocular findings. Success was defined as IOP between 6 and 21\u00a0mmHg and\u2009&gt;\u200920% reduction in IOP with or without anti-glaucoma medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 3\u00a0months follow-up of the first CW-TSCPC treatment, a 24.8% decrease in IOP was observed, whereas a 45.6% IOP decrease was observed 3\u00a0months post the second CW-TSCPC treatment. Visual acuity did not decrease, and no major complications were observed post either treatment within the follow-up period. Time to failure was 79.5\u2009\u00b1\u200924.6 and 77.1\u2009\u00b1\u200929.4, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.955). No serious complications were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A second CW-TSCPC treatment proved to be a safe and effective treatment option when the first CW-TSCPC treatment was insufficient in maintaining the desired IOP level for a prolonged time (mean time between both sessions 6.4\u2009\u00b1\u20098.0\u00a0months).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-022-02234-4","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:03:10Z","timestamp":1643864590000},"page":"2363-2369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["First and second transscleral cyclophotocoagulation treatments provide similar intraocular pressure-lowering efficacy in patients with refractory glaucoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Enrico","family":"Bernardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"T\u00f6teberg-Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"4","key":"2234_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","volume":"40","author":"RJ Casson","year":"2012","unstructured":"Casson RJ, Chidlow G, Wood JPM, Crowston JG, Goldberg I (2012) Definition of glaucoma: clinical and experimental concepts. Clin Experiment Ophthalmol 40(4):341\u2013349. https:\/\/doi.org\/10.1111\/j.1442-9071.2012.02773.x","journal-title":"Clin Experiment Ophthalmol"},{"key":"2234_CR2","doi-asserted-by":"publisher","unstructured":"Lee JWY, Chan PP, Zhang X, Chen LJ, Jonas JB (2019) Latest developments in normal-pressure glaucoma: diagnosis, epidemiology, genetics, etiology, causes and mechanisms to management. Asia-Pacific J. Ophthalmol. (Philadelphia, Pa.) 8(6):457\u2013468. https:\/\/doi.org\/10.1097\/01.APO.0000605096.48529.9c.","DOI":"10.1097\/01.APO.0000605096.48529.9c"},{"issue":"4","key":"2234_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/0301-4738.53049","volume":"57","author":"R Agarwal","year":"2009","unstructured":"Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS (2009) Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol 57(4):257\u2013266. https:\/\/doi.org\/10.4103\/0301-4738.53049","journal-title":"Indian J Ophthalmol"},{"issue":"11","key":"2234_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00347-015-0140-5","volume":"112","author":"M T\u00f6teberg-Harms","year":"2015","unstructured":"T\u00f6teberg-Harms M, Rosentreter A, Lappas A, Funk J, Dietlein TS (2015) Current aspects on the management of normal tension glaucoma. Ophthalmologe 112(11):943\u2013946. https:\/\/doi.org\/10.1007\/s00347-015-0140-5","journal-title":"Ophthalmologe"},{"issue":"10108","key":"2234_CR5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","volume":"390","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S (2017) Glaucoma. Lancet (London, England) 390(10108):2183\u20132193. https:\/\/doi.org\/10.1016\/S0140-6736(17)31469-1","journal-title":"Lancet (London, England)"},{"issue":"9","key":"2234_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00417-018-4011-z","volume":"256","author":"R H\u00f6hn","year":"2018","unstructured":"H\u00f6hn R et al (2018) Prevalence of glaucoma in Germany: results from the Gutenberg Health Study. Graefe\u2019s Arch Clin Exp Ophthalmol 256(9):1695\u20131702. https:\/\/doi.org\/10.1007\/s00417-018-4011-z","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"11","key":"2234_CR7","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y (2014) Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology 121(11):2081\u20132090. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013","journal-title":"Ophthalmology"},{"issue":"12","key":"2234_CR8","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR et al (2017) Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Heal 5(12):e1221\u2013e1234. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5","journal-title":"Lancet Glob Heal"},{"issue":"3","key":"2234_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90(3):262\u2013267. https:\/\/doi.org\/10.1136\/bjo.2005.081224","journal-title":"Br J Ophthalmol"},{"key":"2234_CR10","doi-asserted-by":"publisher","unstructured":"Parihar JKS (2016) Glaucoma: The \u2018Black hole\u2019 of irreversible blindness. Med J Armed Forces India 72(1):3\u20134. https:\/\/doi.org\/10.1016\/j.mjafi.2015.12.001.","DOI":"10.1016\/j.mjafi.2015.12.001"},{"issue":"3","key":"2234_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.pop.2015.05.008","volume":"42","author":"AV Mantravadi","year":"2015","unstructured":"Mantravadi AV, Vadhar N (2015) Glaucoma. Prim Care Clin Off Pract 42(3):437\u2013449. https:\/\/doi.org\/10.1016\/j.pop.2015.05.008","journal-title":"Prim Care Clin Off Pract"},{"issue":"18","key":"2234_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA (2014) The pathophysiology and treatment of glaucoma: a review. JAMA 311(18):1901\u20131911. https:\/\/doi.org\/10.1001\/jama.2014.3192","journal-title":"JAMA"},{"issue":"2","key":"2234_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/ICU.0000000000000551","volume":"30","author":"F Meier-Gibbons","year":"2019","unstructured":"Meier-Gibbons F, Berlin MS, T\u00f6teberg-Harms M (2019) Influence of new treatment modalities on adherence in glaucoma. Curr Opin Ophthalmol 30(2):104\u2013109. https:\/\/doi.org\/10.1097\/ICU.0000000000000551","journal-title":"Curr Opin Ophthalmol"},{"key":"2234_CR14","doi-asserted-by":"publisher","unstructured":"M. Wu et al., \u201cEvaluating Glaucoma Treatment Effect on Intraocular Pressure Reduction Using Propensity Score Weighted Regression.,\u201d Sci. Rep., vol. 9, no. 1, p. 15496, Oct. 2019, doi: https:\/\/doi.org\/10.1038\/s41598-019-52052-5.","DOI":"10.1038\/s41598-019-52052-5"},{"issue":"4","key":"2234_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5694\/mja2.50020","volume":"210","author":"J Lusthaus","year":"2019","unstructured":"Lusthaus J, Goldberg I (2019) Current management of glaucoma. Med J Aust 210(4):180\u2013187. https:\/\/doi.org\/10.5694\/mja2.50020","journal-title":"Med J Aust"},{"key":"2234_CR16","doi-asserted-by":"publisher","unstructured":"L. P. Cohen and L. R. Pasquale, \u201cClinical characteristics and current treatment of glaucoma.,\u201d Cold Spring Harb. Perspect. Med., vol. 4, no. 6, Jun. 2014, doi: https:\/\/doi.org\/10.1101\/cshperspect.a017236.","DOI":"10.1101\/cshperspect.a017236"},{"issue":"2","key":"2234_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICU.0000000000000740","volume":"32","author":"E Ostler","year":"2021","unstructured":"Ostler E, Rhee D, Burney E, Sozeri Y (2021) Advances in medical therapy for glaucoma. Curr Opin Ophthalmol 32(2):129\u2013133. https:\/\/doi.org\/10.1097\/ICU.0000000000000740","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"2234_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","volume":"52","author":"R Conlon","year":"2017","unstructured":"Conlon R, Saheb H, Ahmed IIK (2017) Glaucoma treatment trends: a review. Can J Ophthalmol 52(1):114\u2013124. https:\/\/doi.org\/10.1016\/j.jcjo.2016.07.013","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"2234_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0043-105271","volume":"236","author":"D Jurjevic","year":"2019","unstructured":"Jurjevic D, Funk J, T\u00f6teberg-Harms M (2019) Cyclodestructive procedures to lower intraocular pressure - a review. Klin Monbl Augenheilkd 236(1):63\u201368. https:\/\/doi.org\/10.1055\/s-0043-105271","journal-title":"Klin Monbl Augenheilkd"},{"issue":"13","key":"2234_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3238\/arztebl.2020.0225","volume":"117","author":"AK Schuster","year":"2020","unstructured":"Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N (2020) The diagnosis and treatment of glaucoma. Dtsch Arztebl Int 117(13):225\u2013234. https:\/\/doi.org\/10.3238\/arztebl.2020.0225","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"2234_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1055\/a-0577-7925","volume":"236","author":"R Greslechner","year":"2019","unstructured":"Greslechner R, Spiegel D (2019) Laser trabeculoplasty in modern glaucoma therapy - a review. Klin Monbl Augenheilkd 236(10):1192\u20131200. https:\/\/doi.org\/10.1055\/a-0577-7925","journal-title":"Klin Monbl Augenheilkd"},{"key":"2234_CR22","unstructured":"Douglas M, Gaasterland E (2021) Diode Laser Cyclophotocoagulation. Glaucoma Today. Accessed: Feb. 09, 2021. [Online]. Available: https:\/\/glaucomatoday.com\/articles\/2009-mar\/GT0309_05-php."},{"issue":"2","key":"2234_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/sj.eye.6700286","volume":"17","author":"DE Gaasterland","year":"2003","unstructured":"Gaasterland DE (2003) Regarding assessing G-Probe function. Eye 17(2):123\u2013124. https:\/\/doi.org\/10.1038\/sj.eye.6700286","journal-title":"Eye"},{"key":"2234_CR24","unstructured":"Leszczy\u0144ski R, Gierek-Lapi\u0144ska A, Formi\u0144ska-Kapu\u015bcik M (2004) Transscleral cyclophotocoagulation in the treatment of secondary glaucoma. Med Sci Monit Int Med J Exp Clin Res 10(9): CR542-8."},{"issue":"1","key":"2234_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10792-017-0782-1","volume":"39","author":"JJC Cheung","year":"2019","unstructured":"Cheung JJC, Li KKW, Tang SWK (2019) Retrospective review on the outcome and safety of transscleral diode laser cyclophotocoagulation in refractory glaucoma in Chinese patients. Int Ophthalmol 39(1):41\u201346. https:\/\/doi.org\/10.1007\/s10792-017-0782-1","journal-title":"Int Ophthalmol"},{"key":"2234_CR26","doi-asserted-by":"publisher","unstructured":"Michelessi M, Bicket AK, Lindsley K (2018) Cyclodestructive procedures for non-refractory glaucoma. Cochrane Database Syst Rev 4(4):CD009313. https:\/\/doi.org\/10.1002\/14651858.CD009313.pub2.","DOI":"10.1002\/14651858.CD009313.pub2"},{"key":"2234_CR27","doi-asserted-by":"publisher","unstructured":"Fankhauser F, Kwasniewska S (2004) Cyclodestructive procedures. II. Optical fibers, endoscopy, physics: a review. Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd 218(3):147\u2013161. https:\/\/doi.org\/10.1159\/000076839.","DOI":"10.1159\/000076839"},{"issue":"12","key":"2234_CR28","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/bjo.2007.116533","volume":"91","author":"ME Iliev","year":"2007","unstructured":"Iliev ME, Gerber S (2007) Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 91(12):1631\u20131635. https:\/\/doi.org\/10.1136\/bjo.2007.116533","journal-title":"Br J Ophthalmol"},{"key":"2234_CR29","first-page":"225","volume":"90","author":"DE Gaasterland","year":"1992","unstructured":"Gaasterland DE, Pollack IP (1992) Initial experience with a new method of laser transscleral cyclophotocoagulation for ciliary ablation in severe glaucoma. Trans Am Ophthalmol Soc 90:225\u2013226","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2234_CR30","doi-asserted-by":"publisher","unstructured":"Chen MF, Kim CH, Coleman AL (2016) Cyclodestructive procedures for refractory glaucoma. Cochrane Database Syst Rev (3). https:\/\/doi.org\/10.1002\/14651858.cd012223.","DOI":"10.1002\/14651858.cd012223"},{"key":"2234_CR31","doi-asserted-by":"publisher","unstructured":"Osman EA, Al-Muammar A, Mousa A, Al-Mezaine H, Al-Obeidan SA (2010) Controlled Cyclophotocoagulation with diode laser in refractory glaucoma and long term follow up at King Abdulaziz University Hospital, Riyadh. Saudi J Ophthalmol Off J Saudi Ophthalmol Soc 24(1):9\u201313. https:\/\/doi.org\/10.1016\/j.sjopt.2009.12.002.","DOI":"10.1016\/j.sjopt.2009.12.002"},{"issue":"3","key":"2234_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/IJG.0b013e318207091a","volume":"21","author":"N Ramli","year":"2012","unstructured":"Ramli N, Htoon HM, Ho CL, Aung T, Perera S (2012) Risk factors for hypotony after transscleral diode cyclophotocoagulation. J Glaucoma 21(3):169\u2013173. https:\/\/doi.org\/10.1097\/IJG.0b013e318207091a","journal-title":"J Glaucoma"},{"issue":"8","key":"2234_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/aos.14125","volume":"97","author":"E Rasmuson","year":"2019","unstructured":"Rasmuson E, Lind\u00e9n C, Lundberg B, J\u00f3hannesson G (2019) Efficacy and safety of transscleral cyclophotocoagulation in Swedish glaucoma patients. Acta Ophthalmol 97(8):764\u2013770. https:\/\/doi.org\/10.1111\/aos.14125","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2234_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2003.11.008","volume":"111","author":"JT Wilensky","year":"2004","unstructured":"Wilensky JT, Kammer J (2004) Long-term visual outcome of transscleral laser cyclotherapy in eyes with ambulatory vision. Ophthalmology 111(7):1389\u20131392. https:\/\/doi.org\/10.1016\/j.ophtha.2003.11.008","journal-title":"Ophthalmology"},{"key":"2234_CR35","doi-asserted-by":"publisher","unstructured":"S. Souissi et al. (2020) An update on continuous-wave cyclophotocoagulation (CW-CPC) and micropulse transscleral laser treatment (MP-TLT) for adult and paediatric refractory glaucoma. Acta Ophthalmol https:\/\/doi.org\/10.1111\/aos.14661.","DOI":"10.1111\/aos.14661"},{"issue":"3","key":"2234_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1062860607300652","volume":"22","author":"HM Kroon","year":"2007","unstructured":"Kroon HM, Breslau PJ, Lardenoye JWHP (2007) Can the incidence of unplanned reoperations be used as an indicator of quality of care in surgery? Am J Med Qual Off J Am Coll Med Qual 22(3):198\u2013202. https:\/\/doi.org\/10.1177\/1062860607300652","journal-title":"Am J Med Qual Off J Am Coll Med Qual"},{"issue":"2","key":"2234_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IJG.0000000000000533","volume":"26","author":"YC Hsia","year":"2017","unstructured":"Hsia YC et al (2017) Early Reoperation Rate, Complication, and Outcomes in Resident-performed Glaucoma Surgery. J Glaucoma 26(2):87\u201392. https:\/\/doi.org\/10.1097\/IJG.0000000000000533","journal-title":"J Glaucoma"},{"issue":"5","key":"2234_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/IJG.0000000000001484","volume":"29","author":"C-K Chu","year":"2020","unstructured":"Chu C-K, Liebmann JM, Cioffi GA, Blumberg DM, Al-Aswad LA (2020) Reoperations for Complications Within 90 Days After Glaucoma Surgery. J Glaucoma 29(5):344\u2013346. https:\/\/doi.org\/10.1097\/IJG.0000000000001484","journal-title":"J Glaucoma"},{"issue":"8","key":"2234_CR39","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/ceo.12088","volume":"41","author":"JS Aujla","year":"2013","unstructured":"Aujla JS, Lee GA, Vincent SJ, Thomas R (2013) Incidence of hypotony and sympathetic ophthalmia following trans-scleral cyclophotocoagulation for glaucoma and a report of risk factors. Clin Experiment Ophthalmol 41(8):761\u2013772. https:\/\/doi.org\/10.1111\/ceo.12088","journal-title":"Clin Experiment Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s10792-022-02249-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000}}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02234-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T05:22:58Z","timestamp":1658726578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02234-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02234-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10792-022-02249-x","URL":"https:\/\/doi.org\/10.1007\/s10792-022-02249-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EB: None. MTH: Allergan \/ Abbvie: Consultant\/Advisor, Lecture Fees; Eyelight: Consultant\/Advisor; ELT Sight: Consultant\/Advisor; Glaukos Corporation: Lecture Fees; Heidelberg Engineering: Lecture Fees; IRIDEX: Consultant\/Advisor, Lecture Fees, Travel Reimbursement, Research Grant; MLase AG: Consultant\/Advisor, Lecture Fees; Novartis, Alcon Pharmaceuticals: Lecture Fees; Reichert: Consultant\/Advisor, Lecture Fees; Santen, Inc.: Consultant\/Advisor, Lecture Fees, Research Grant; Th\u00e9a Pharma: Lecture Fees. MTH is a consultant for Iridex. In addition, he received lecture fees and travel reimbursement from Iridex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee (cantonal ethics committee of the canton of Zurich, registration ID 2020\u201300,219).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients who decided not to participate in research (negative general consent) were excluded. Consent for publication. Data from patients with a valid signed general consent were included. In cases, a general consent or a negative general consent was not available, an informed consent was obtained. Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}